212 related articles for article (PubMed ID: 24984960)
21. Therapeutic Activity of Anti-AXL Antibody against Triple-Negative Breast Cancer Patient-Derived Xenografts and Metastasis.
Leconet W; Chentouf M; du Manoir S; Chevalier C; Sirvent A; Aït-Arsa I; Busson M; Jarlier M; Radosevic-Robin N; Theillet C; Chalbos D; Pasquet JM; Pèlegrin A; Larbouret C; Robert B
Clin Cancer Res; 2017 Jun; 23(11):2806-2816. PubMed ID: 27923843
[No Abstract] [Full Text] [Related]
22. Loss of Smad4 in colorectal cancer induces resistance to 5-fluorouracil through activating Akt pathway.
Zhang B; Zhang B; Chen X; Bae S; Singh K; Washington MK; Datta PK
Br J Cancer; 2014 Feb; 110(4):946-57. PubMed ID: 24384683
[TBL] [Abstract][Full Text] [Related]
23. MPPa-PDT suppresses breast tumor migration/invasion by inhibiting Akt-NF-κB-dependent MMP-9 expression via ROS.
Huang L; Lin H; Chen Q; Yu L; Bai D
BMC Cancer; 2019 Nov; 19(1):1159. PubMed ID: 31783821
[TBL] [Abstract][Full Text] [Related]
24. Differential expression of Axl and correlation with invasion and multidrug resistance in cancer cells.
Zhao Y; Sun X; Jiang L; Yang F; Zhang Z; Jia L
Cancer Invest; 2012 May; 30(4):287-94. PubMed ID: 22489801
[TBL] [Abstract][Full Text] [Related]
25. Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer.
Linger RM; Cohen RA; Cummings CT; Sather S; Migdall-Wilson J; Middleton DH; Lu X; Barón AE; Franklin WA; Merrick DT; Jedlicka P; DeRyckere D; Heasley LE; Graham DK
Oncogene; 2013 Jul; 32(29):3420-31. PubMed ID: 22890323
[TBL] [Abstract][Full Text] [Related]
26. ΔNp63α Promotes Breast Cancer Cell Motility through the Selective Activation of Components of the Epithelial-to-Mesenchymal Transition Program.
Dang TT; Esparza MA; Maine EA; Westcott JM; Pearson GW
Cancer Res; 2015 Sep; 75(18):3925-35. PubMed ID: 26292362
[TBL] [Abstract][Full Text] [Related]
27. Opposite regulation by PI3K/Akt and MAPK/ERK pathways of tissue factor expression, cell-associated procoagulant activity and invasiveness in MDA-MB-231 cells.
Hu C; Huang L; Gest C; Xi X; Janin A; Soria C; Li H; Lu H
J Hematol Oncol; 2012 Jul; 5():16. PubMed ID: 22534171
[TBL] [Abstract][Full Text] [Related]
28. Loss of NDRG2 promotes epithelial-mesenchymal transition of gallbladder carcinoma cells through MMP-19-mediated Slug expression.
Lee DG; Lee SH; Kim JS; Park J; Cho YL; Kim KS; Jo DY; Song IC; Kim N; Yun HJ; Park YJ; Lee SJ; Lee HG; Bae KH; Lee SC; Shim S; Kim YM; Kwon YG; Kim JM; Lee HJ; Min JK
J Hepatol; 2015 Dec; 63(6):1429-39. PubMed ID: 26292259
[TBL] [Abstract][Full Text] [Related]
29. Skipping of exon 10 in
Shen L; Lei S; Zhang B; Li S; Huang L; Czachor A; Breitzig M; Gao Y; Huang M; Mo X; Zheng Q; Sun H; Wang F
Theranostics; 2020; 10(13):5719-5735. PubMed ID: 32483414
[TBL] [Abstract][Full Text] [Related]
30. Casticin inhibits breast cancer cell migration and invasion by down-regulation of PI3K/Akt signaling pathway.
Fan L; Zhang Y; Zhou Q; Liu Y; Gong B; Lü J; Zhu H; Zhu G; Xu Y; Huang G
Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30401729
[TBL] [Abstract][Full Text] [Related]
31. Bmi-1 promotes invasion and metastasis, and its elevated expression is correlated with an advanced stage of breast cancer.
Guo BH; Feng Y; Zhang R; Xu LH; Li MZ; Kung HF; Song LB; Zeng MS
Mol Cancer; 2011 Jan; 10(1):10. PubMed ID: 21276221
[TBL] [Abstract][Full Text] [Related]
32. Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway.
Ramaswamy B; Lu Y; Teng KY; Nuovo G; Li X; Shapiro CL; Majumder S
Cancer Res; 2012 Oct; 72(19):5048-59. PubMed ID: 22875023
[TBL] [Abstract][Full Text] [Related]
33. YES-associated protein 1 promotes adenocarcinoma growth and metastasis through activation of the receptor tyrosine kinase Axl.
Cui ZL; Han FF; Peng XH; Chen X; Luan CY; Han RC; Xu WG; Guo XJ
Int J Immunopathol Pharmacol; 2012; 25(4):989-1001. PubMed ID: 23298489
[TBL] [Abstract][Full Text] [Related]
34. ERalpha signaling through slug regulates E-cadherin and EMT.
Ye Y; Xiao Y; Wang W; Yearsley K; Gao JX; Shetuni B; Barsky SH
Oncogene; 2010 Mar; 29(10):1451-62. PubMed ID: 20101232
[TBL] [Abstract][Full Text] [Related]
35. Suppression of the metastatic spread of breast cancer by DN10764 (AZD7762)-mediated inhibition of AXL signaling.
Park JS; Lee C; Kim HK; Kim D; Son JB; Ko E; Cho JH; Kim ND; Nan HY; Kim CY; Yoon S; Lee SH; Choi HG
Oncotarget; 2016 Dec; 7(50):83308-83318. PubMed ID: 27829217
[TBL] [Abstract][Full Text] [Related]
36. Upregulated WDR26 serves as a scaffold to coordinate PI3K/ AKT pathway-driven breast cancer cell growth, migration, and invasion.
Ye Y; Tang X; Sun Z; Chen S
Oncotarget; 2016 Apr; 7(14):17854-69. PubMed ID: 26895380
[TBL] [Abstract][Full Text] [Related]
37. MicroRNA-130b targets PTEN to mediate drug resistance and proliferation of breast cancer cells via the PI3K/Akt signaling pathway.
Miao Y; Zheng W; Li N; Su Z; Zhao L; Zhou H; Jia L
Sci Rep; 2017 Feb; 7():41942. PubMed ID: 28165066
[TBL] [Abstract][Full Text] [Related]
38. Axl phosphorylates Elmo scaffold proteins to promote Rac activation and cell invasion.
Abu-Thuraia A; Gauthier R; Chidiac R; Fukui Y; Screaton RA; Gratton JP; Côté JF
Mol Cell Biol; 2015 Jan; 35(1):76-87. PubMed ID: 25332238
[TBL] [Abstract][Full Text] [Related]
39. Blueberry phytochemicals inhibit growth and metastatic potential of MDA-MB-231 breast cancer cells through modulation of the phosphatidylinositol 3-kinase pathway.
Adams LS; Phung S; Yee N; Seeram NP; Li L; Chen S
Cancer Res; 2010 May; 70(9):3594-605. PubMed ID: 20388778
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic activity of DCC-2036, a novel tyrosine kinase inhibitor, against triple-negative breast cancer patient-derived xenografts by targeting AXL/MET.
Shen Y; Zhang W; Liu J; He J; Cao R; Chen X; Peng X; Xu H; Zhao Q; Zhong J; Ding W; Lei X; Jiang Y; Zu X
Int J Cancer; 2019 Feb; 144(3):651-664. PubMed ID: 30289981
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
